Christopher L. Reyes,Peter Chu,Kristen M. Smith,Lioudmila A. Campbell,Farbod Shojaei,John Thomas Norton
申请号：
US16449154
公开号：
US20190389964A1
申请日:
2019.06.21
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
